This is for anyone interested in understanding the reasoning behind this treatment and what will most likely be recommended in the future. I think understanding 'the other side' gives us an advantage in developing our counter-approach.
Provisional recommendations for Group B Streptococcus prevention and control
Group B Streptococcus (GBS) has been the leading infectious cause of early neonatal morbidity and mortality in the United States since the early 1970s. However, the incidence of early-onset neonatal GBS disease has declined approximately 80 percent since the early 1990s. This drastic decrease is largely due to the Guidelines for Prevention of Perinatal Group B Streptococcal Disease initially issued by the CDC in 1996 and revised in 2002. Unfortunately, GBS remains a major burden of disease in neonates. New data has prompted another revision to the Guidelines for Prevention of Perinatal Group B Streptococcal Disease. Provisional recommendations have been posted on the CDC website. Once finalized, the new guidelines will be published in the CDC’s Morbidity and Mortality Weekly Report (MMWR), tentatively scheduled for November, 2010.
The provisional revisions include:
New algorithms for the management of women with onset of labor or rupture of membranes <37 weeks
Updated procedures and methods for collection and processing of GBS specimens
A new algorithm of recommendations for intrapartum antibiotic prophylaxis agents and dosages
A new algorithm for detecting early-onset GBS cases in newborns